# The EMPrint™ Ablate and RESect Study in Patients With Metastatic Lung Tumors (EMPRESS)

> **NCT02323854** · NA · COMPLETED · sponsor: **Medtronic - MITG** · enrollment: 15 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DEVICE:** Ablation
- **PROCEDURE:** Surgical Resection

## Key facts

- **NCT ID:** NCT02323854
- **Lead sponsor:** Medtronic - MITG
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2017-03-13
- **Final completion:** 2017-11
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2018-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02323854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02323854, "The EMPrint™ Ablate and RESect Study in Patients With Metastatic Lung Tumors (EMPRESS)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02323854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*